Literature DB >> 11899241

The molecular basis of type 1 glycogen storage diseases.

J Y Chou1.   

Abstract

Glycogen storage disease type 1 (GSD-1), also known as von Gierke disease, is a group of autosomal recessive metabolic disorders caused by deficiencies in the activity of the glucose-6-phosphatase (G6Pase) system that consists of at least two membrane proteins, glucose-6-phosphate transporter (G6PT) and G6Pase. G6PT translocates glucose-6-phosphate (G6P) from cytoplasm to the lumen of the endoplasmic reticulum (ER) and G6Pase catalyzes the hydrolysis of G6P to produce glucose and phosphate. Therefore, G6PT and G6Pase work in concert to maintain glucose homeostasis. Deficiencies in G6Pase and G6PT cause GSD-1a and GSD-1b, respectively. Both manifest functional G6Pase deficiency characterized by growth retardation, hypoglycemia, hepatomegaly, kidney enlargement, hyperlipidemia, hyperuricemia, and lactic acidemia. GSD-1b patients also suffer from chronic neutropenia and functional deficiencies of neutrophils and monocytes, resulting in recurrent bacterial infections as well as ulceration of the oral and intestinal mucosa. The G6Pase gene maps to chromosome 17q21 and encodes a 36-kDa glycoprotein that is anchored to the ER by 9 transmembrane helices with its active site facing the lumen. Animal models of GSD-1a have been developed and are being exploited to delineate the disease more precisely and to develop new therapies. The G6PT gene maps to chromosome 11q23 and encodes a 37-kDa protein that is anchored to the ER by 10 transmembrane helices. A functional assay for the recombinant G6PT protein has been established, which showed that G6PT functions as a G6P transporter in the absence of G6Pase. However, microsomal G6P uptake activity was markedly enhanced in the simultaneous presence of G6PT and G6Pase. The cloning of the G6PT gene now permits animal models of GSD-1b to be generated. These recent developments are increasing our understanding of the GSD-l disorders and the G6Pase system, knowledge that will facilitate the development of novel therapeutic approaches for these disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11899241     DOI: 10.2174/1566524013364112

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  12 in total

Review 1.  Periodontal and other oral manifestations of immunodeficiency diseases.

Authors:  M E Peacock; R M Arce; C W Cutler
Journal:  Oral Dis       Date:  2016-10-10       Impact factor: 3.511

2.  Cutting Edge: Increased Autoimmunity Risk in Glycogen Storage Disease Type 1b Is Associated with a Reduced Engagement of Glycolysis in T Cells and an Impaired Regulatory T Cell Function.

Authors:  Daniela Melis; Fortunata Carbone; Giorgia Minopoli; Claudia La Rocca; Francesco Perna; Veronica De Rosa; Mario Galgani; Generoso Andria; Giancarlo Parenti; Giuseppe Matarese
Journal:  J Immunol       Date:  2017-04-07       Impact factor: 5.422

3.  SRC-2 orchestrates polygenic inputs for fine-tuning glucose homeostasis.

Authors:  Tiffany Fleet; Bin Zhang; Fumin Lin; Bokai Zhu; Subhamoy Dasgupta; Erin Stashi; Bryan Tackett; Sundararajah Thevananther; Kimal I Rajapakshe; Naomi Gonzales; Adam Dean; Jianqiang Mao; Nikolai Timchenko; Anna Malovannaya; Jun Qin; Cristian Coarfa; Francesco DeMayo; Clifford C Dacso; Charles E Foulds; Bert W O'Malley; Brian York
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-20       Impact factor: 11.205

4.  Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector.

Authors:  Albert Grinshpun; Reba Condiotti; Simon N Waddington; Michael Peer; Eli Zeig; Sima Peretz; Alina Simerzin; Janice Chou; Chi-Jiunn Pann; Hilla Giladi; Eithan Galun
Journal:  Mol Ther       Date:  2010-06-22       Impact factor: 11.454

Review 5.  Biochemical and clinical aspects of glycogen storage diseases.

Authors:  Sara S Ellingwood; Alan Cheng
Journal:  J Endocrinol       Date:  2018-06-06       Impact factor: 4.286

Review 6.  Induced pluripotent stem cells for modelling human diseases.

Authors:  Juli J Unternaehrer; George Q Daley
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-08-12       Impact factor: 6.237

7.  Gene expression profiles of hepatic cell-type specific marker genes in progression of liver fibrosis.

Authors:  Yoshiyuki Takahara; Mitsuo Takahashi; Hiroki Wagatsuma; Fumihiko Yokoya; Qing-Wei Zhang; Mutsuyo Yamaguchi; Hiroyuki Aburatani; Norifumi Kawada
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

Review 8.  Infections in patients with inherited defects in phagocytic function.

Authors:  Timothy Andrews; Kathleen E Sullivan
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

9.  Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels.

Authors:  Atfa Sassi; Sandra Lazaroski; Gang Wu; Stuart M Haslam; Manfred Fliegauf; Fethi Mellouli; Turkan Patiroglu; Ekrem Unal; Mehmet Akif Ozdemir; Zineb Jouhadi; Khadija Khadir; Leila Ben-Khemis; Meriem Ben-Ali; Imen Ben-Mustapha; Lamia Borchani; Dietmar Pfeifer; Thilo Jakob; Monia Khemiri; A Charlotta Asplund; Manuela O Gustafsson; Karin E Lundin; Elin Falk-Sörqvist; Lotte N Moens; Hatice Eke Gungor; Karin R Engelhardt; Magdalena Dziadzio; Hans Stauss; Bernhard Fleckenstein; Rebecca Meier; Khairunnadiya Prayitno; Andrea Maul-Pavicic; Sandra Schaffer; Mirzokhid Rakhmanov; Philipp Henneke; Helene Kraus; Hermann Eibel; Uwe Kölsch; Sellama Nadifi; Mats Nilsson; Mohamed Bejaoui; Alejandro A Schäffer; C I Edvard Smith; Anne Dell; Mohamed-Ridha Barbouche; Bodo Grimbacher
Journal:  J Allergy Clin Immunol       Date:  2014-04-01       Impact factor: 10.793

Review 10.  Minireview: Genome Editing of Human Pluripotent Stem Cells for Modeling Metabolic Disease.

Authors:  Haojie Yu; Chad A Cowan
Journal:  Mol Endocrinol       Date:  2016-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.